OpenAI’s closed-access biology LLM entrenches corporate control over life sciences data, deepening extractive AI monopolies
Original framing: “OpenAI starts offering a biology-tuned LLM” — Ars Technica
The original framing omits the historical context of corporate enclosure of scientific knowledge, such as the privatisation of genetic data through patents and the legacy of colonial biopiracy. It also ignores the role of indigenous knowledge systems in biological research, which have long contributed to biodiversity conservation and medicinal breakthroughs. Additionally, the framing neglects the structural inequities in AI development, where Global South researchers are often excluded from access to cutting-edge tools due to cost and licensing barriers.
Medium structural omission detected in mainstream coverage.
The narrative is produced by Ars Technica, a tech-focused outlet that often amplifies Silicon Valley’s framing of AI as a neutral, progressive force. This framing serves the interests of OpenAI and its investors by normalising closed-access AI models as inevitable and beneficial, while obscuring the power asymmetries they create. The framing also aligns with the broader tech industry’s push to position itself as the sole arbiter of scientific progress, marginalising public institutions and open science movements.
Scientifically, closed-access AI models like GPT-Rosalind risk limiting the reproducibility and transparency of biological research, as proprietary systems obscure methodological details. Open-access alternatives, such as those developed by the European Bioinformatics Institute, have demonstrated that collaborative models accelerate scientific discovery. Additionally, the lack of peer review in proprietary AI tools raises concerns about bias and error propagation in biological research. The scientific community has long advocated for open data and reproducible methods to ensure robust and equitable progress.
The launch of GPT-Rosalind exemplifies the techno-feudalisation of science, where a Silicon Valley corporation centralises control over biological knowledge under the guise of innovation.